- Previous Close
0.0090 - Open
0.0100 - Bid 0.0090 x --
- Ask 0.0100 x --
- Day's Range
0.0090 - 0.0100 - 52 Week Range
0.0020 - 0.0190 - Volume
11,056,590 - Avg. Volume
28,092,973 - Market Cap (intraday)
64.115M - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.04
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
alteritytherapeutics.comRecent News: ATH.AX
View More
Performance Overview: ATH.AX
Trailing total returns as of 3/11/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATH.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATH.AX
View MoreValuation Measures
Market Cap
57.70M
Enterprise Value
53.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.41
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-78.37%
Return on Equity (ttm)
-155.77%
Revenue (ttm)
3.72M
Net Income Avi to Common (ttm)
-19.79M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
4.54M
Total Debt/Equity (mrq)
1.36%
Levered Free Cash Flow (ttm)
-8.87M
Research Analysis: ATH.AX
View MoreCompany Insights: ATH.AX
ATH.AX does not have Company Insights